Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins.
暂无分享,去创建一个
Michael Levin | David Burgner | Martin L Hibberd | Jane C Burns | C. Khor | V. Wright | M. Hibberd | M. Levin | J. Burns | T. Kuijpers | Kei Takahashi | D. Burgner | C. Shimizu | S. Davila | W. Breunis | Victoria J Wright | Taco W Kuijpers | Chisato Shimizu | Sonia Davila | Willemijn B Breunis | Toshiaki Oharaseki | Kei Takahashi | Michel van Houdt | Chiea Chuen Khor | M. van Houdt | T. Oharaseki
[1] S. Karpatkin,et al. Thrombin Induces the Release of Angiopoietin-1 from Platelets , 2001, Thrombosis and Haemostasis.
[2] G. Lip,et al. Plasma Angiopoietin-1, Angiopoietin-2, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor Levels in Acute Coronary Syndromes , 2004, Circulation.
[3] Y. Kohno,et al. Vascular endothelial growth factor in acute Kawasaki disease. , 1999, The American journal of cardiology.
[4] S. Nonoyama,et al. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease , 2005, Clinical and experimental immunology.
[5] C. Yutani,et al. Remodeling of coronary artery lesions due to Kawasaki disease: comparison of arteriographic and immunohistochemical findings. , 2000, Japanese heart journal.
[6] A. Markham,et al. Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2 , 2002, Cytogenetic and Genome Research.
[7] Y. Hamashima,et al. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome , 1978, European Journal of Pediatrics.
[8] D. Ray,et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. , 2003, Cancer research.
[9] Walter R Wilson,et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Pediatrics.
[10] M. Barakat,et al. VEGF inhibitors for the treatment of neovascular age-related macular degeneration , 2009, Expert opinion on investigational drugs.
[11] N. Glazer,et al. Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.
[12] Y. Kohno,et al. Systemic Production of Vascular Endothelial Growth Factor and fms-Like Tyrosine Kinase-1 Receptor in Acute Kawasaki Disease , 2002, Circulation.
[13] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[14] Richard A. Lang,et al. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[15] Naoko Kinukawa,et al. Association of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Gene Polymorphisms with Coronary Artery Lesions of Kawasaki Disease , 2004, Pediatric Research.
[16] S. Karpatkin,et al. Identification of a family of alternatively spliced mRNA species of angiopoietin-1. , 2000, Blood.
[17] H. Kanegane,et al. Neutrophils and Mononuclear Cells Express Vascular Endothelial Growth Factor in Acute Kawasaki Disease: Its Possible Role in Progression of Coronary Artery Lesions , 2001, Pediatric Research.
[18] H. Verheul,et al. Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] D. Fliser,et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients , 2008, Critical care.
[20] Panayiotis V. Benos,et al. STAMP: a web tool for exploring DNA-binding motif similarities , 2007, Nucleic Acids Res..
[21] Gavin Thurston,et al. Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.
[22] Angiopoietin-1, angiopoietin-2 and tie-2 in the coronary circulation of patients with and without coronary collateral vessels. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[23] S. Crawford,et al. Systemic Arterial Expression of Matrix Metalloproteinases 2 and 9 in Acute Kawasaki Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[24] H Yanagawa,et al. Kawasaki disease in parents and children , 2003, Acta paediatrica.
[25] Douglas Hanahan,et al. Signaling Vascular Morphogenesis and Maintenance , 1997, Science.
[26] T. Hara,et al. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease , 2000, European Journal of Pediatrics.
[27] A. Freeman,et al. Angiogenesis in Fatal Acute Kawasaki Disease Coronary Artery and Myocardium , 2005, Pediatric Cardiology.
[28] B. Witzenbichler,et al. Protective Role of Angiopoietin-1 in Endotoxic Shock , 2005, Circulation.
[29] A. Grothey,et al. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules , 2009, Nature Reviews Clinical Oncology.
[30] H. Augustin,et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.
[31] Kei Takahashi,et al. Kawasaki Disease With Particular Emphasis on Arterial Lesions , 1991, Acta pathologica japonica.
[32] H. Augustin,et al. Angiopoietins: a link between angiogenesis and inflammation. , 2006, Trends in immunology.
[33] Y. Hamashima,et al. Pathology of the heart in Kawasaki disease. , 1978, Pediatrics.
[34] R. Uehara,et al. Epidemiologic Features of Kawasaki Disease in Japan: Results from the Nationwide Survey in 2005-2006 , 2008, Journal of epidemiology.
[35] Y. Hamashima,et al. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. , 1979, Japanese circulation journal.
[36] M. van Meurs,et al. Bench-to-bedside review: Angiopoietin signalling in critical illness – a future target? , 2009, Critical care.
[37] S. Crawford,et al. Cell Adhesion Molecule Expression in Coronary Artery Aneurysms in Acute Kawasaki Disease , 2004, The Pediatric infectious disease journal.
[38] K. Kain,et al. Serum Angiopoietin-1 and -2 Levels Discriminate Cerebral Malaria from Uncomplicated Malaria and Predict Clinical Outcome in African Children , 2009, PloS one.
[39] S. Chanock,et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. , 2006, Arthritis and rheumatism.
[40] I. Maruyama,et al. Increased Serum Levels of Vascular Endothelial Growth Factor in Kawasaki Disease , 1998, Pediatric Research.
[41] G. Yancopoulos,et al. The anti-inflammatory actions of angiopoietin-1. , 2005, EXS.
[42] V. Pravica,et al. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. , 1999, Human immunology.
[43] Anbupalam Thalamuthu,et al. A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki Disease , 2009, PLoS genetics.